Preschool ADHD First-Medication Choice Card
A guide to help parents and doctors choose the first ADHD medication for a preschooler.
A point-of-care shared-decision card for parents and developmental-behavioral pediatricians choosing a preschooler's first ADHD medication, showing real-world improvement and side-effect rates for stimulants vs α2-adrenergic agonists, then printing a class-matched monitoring checklist.
Concept
A one-page digital (or paper) shared-decision card used at the single moment a preschool child (under 72 months) with ADHD starts medication. It presents the first real-world head-to-head numbers: stimulants were followed by reported improvement in 78% of children vs 66% for α2-adrenergic agonists, with clearly divergent side-effect burdens — daytime sleepiness 38% vs 3% for α2-agonists; moodiness/irritability 50% vs 29%, appetite suppression 38% vs 7%, and sleep difficulty 21% vs 11% for stimulants. Parents mark which side effects matter most for their child (a picky eater, a poor sleeper, a child in daycare who cannot afford daytime sedation), the clinician and family choose a class together, and the card prints a class-matched monitoring checklist covering the typical initial trial period (median first-use duration was ~133–136 days): weight and appetite checks for stimulants, daytime-sedation checks for α2-agonists. One decision, one visit, one checklist.
Why now
Paper [4] abstracted 497 consecutive preschool-age children (median age 62 months, 82% male) from 7 US developmental-behavioral pediatric practices and quantified, for the first time in a real-world sample, both the improvement rates and the distinct adverse-effect profiles of the two medication classes — at a moment when up to 25–35% of preschoolers are started on α2-agonists despite minimal evidence and despite stimulants being the guideline-recommended first-line choice. The data are retrospective, so the card is framed honestly as shared decision support rather than a directive — precisely the gap the authors identify while awaiting randomized trials. Older corpus paper [9] establishes the pharmacological menu for childhood ADHD, but nothing in current guidelines or the existing catalog gives preschool families a quantified class-choice aid with class-matched monitoring.
Written by GLM · 12 Oct 2026
AI assessment
A highly focused, evidence-backed decision support tool that solves a specific clinical friction point in preschool ADHD medication initiation.
- Evidence strength 5/5
- The idea directly translates the specific percentages and outcomes from a real-world study of 497 children into a clinical tool, matching the research's findings on efficacy and side-effect divergence.
- Market pull 4/5
- Developmental-behavioral pediatricians face high pressure to manage parent expectations and side-effect concerns during the high-stakes first medication trial.
- Novelty & moat 4/5
- While other ADHD tools in the catalog focus on long-term monitoring or non-drug options, this is the first to target the specific 'first-choice' moment for the preschool demographic.
- Feasibility 5/5
- The MVP is a simple digital or paper-based decision matrix and checklist, requiring no complex software or clinical trials to implement.
- Wedge clarity 5/5
- The wedge is extremely sharp: a single-visit, one-page tool used at the exact moment of medication initiation.
- Simplicity / focus 5/5
- It avoids 'platform' creep by focusing on one specific decision and one specific output (the monitoring checklist).
Scored by Gemma 4 · 12 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
Its member practices supplied the comparative data and are the natural first users; the card standardizes a decision their clinicians currently make with minimal preschool-specific evidence.
- American Academy of Pediatricsorganization
It publishes the child ADHD guidelines that recommend stimulants first-line in preschoolers; a quantified shared-decision aid operationalizes that guidance where real practice diverges from it.
- CHADDorganization
The largest US ADHD family-advocacy organization; parents of newly diagnosed preschoolers need exactly this kind of plain-language, numbers-based comparison when facing a first medication decision.
- Brightlinecompany
A pediatric behavioral-health telehealth provider whose clinicians prescribe to young children; embedding the card differentiates its medication-initiation visits with evidence parents can see.
Research it builds on
- Evidence-based pharmacological treatment options for ADHD in children and adolescentsKonstantin Mechler, Tobias Banaschewski, Sarah Hohmann et al. · 2021 · 296 citationsAll ideas from this paper →
- α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity DisorderElizabeth B. Harstad, Justine Shults, William Joseph Barbaresi et al. · 2021 · 43 citationsAll ideas from this paper →